Tie-Up With MedImmune Marks Catalyst's Second Partnership Deal In A Week
This article was originally published in The Pink Sheet Daily
Executive Summary
The collaboration involves discovery work on undisclosed targets in the autoimmune and inflammatory disease areas.
You may also be interested in...
With Factor VIIa Tie-up, Wyeth And Catalyst Look To Take On Novo Nordisk
In their second collaboration, the pharma and the biotech aim to develop a longer-acting, more potent hemophilia drug.
AstraZeneca Concentrates Biologics At MedImmune, Ups R&D
MedImmune, which absorbs Cambridge Antibody Technologies, will continue to operate independently from AstraZeneca.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.